课题基金 / 基金详情

Planning & Evaluation Core

Planning & Evaluation Core
规划
批准号:
10756838
负责人:
Julian A Simon
金额:
$10.42万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
未结题
起止时间:
2007-09-30 至 2028-08-31

项目摘要

项目成果

Julian A Simon的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 癌症研究促进伙伴关系的规划和评估核心(P&E核心) 新墨西哥州立大学(NMSU)和弗雷德·哈钦森癌症中心(弗雷德·哈奇)之间的坐标 确定伙伴关系活动在以下方面的影响和效力所需的关键职能 实现其目标和目的。P&E Core主管,NMSU的Rachel Boren博士和Julian Simon博士 弗雷德·哈奇在项目评估方法方面拥有丰富的专业知识。博伦博士是世界卫生组织 新墨西哥州西南外展学术研究(SOAR)评估和政策中心 他是一名大学教师,担任评价员已有10多年。她之前曾担任过 位于华盛顿大学的转化性健康科学研究所(IIHS)。弗雷德·哈奇隶属于 与华盛顿大学合作,并参与了Iths,从而使博伦博士对 两个机构都是。西蒙博士曾担任研究项目和核心负责人,目前担任MPI 合作伙伴关系。他在伙伴关系中近20年的参与使他对 合作的文化。P&E核心的五个具体目标是:1.提供评估工具以 评价、跟踪和报告伙伴关系各方面的进展情况;2.发布申请申请 对于新的试点和全面研究项目,并对提案进行严格审查;3.吸引社区参与 成员和社区行动委员会评估伙伴关系对推进区域癌症的影响 卫生公平;4.召集IAC和PSC审查核心和研究项目的进展情况,并促进 咨询机构、NCI、CORE和项目领导之间的沟通;5.评估 指导原则的实施和影响(总体详细描述)。为了完成 这些目标,P&E核心将与MPI(Graciela Unguez博士和Julian Simon博士)以及 研究项目和核心领导开发适当的评估工具,以告知有效性 该伙伴关系的活动。将收集和评估结果的定量和定性衡量标准 基于逻辑模型中描述的指标(参见P&E核心)。将征集新的研究项目, 通过P&E核心进行评估和实施。将对当前研究项目和核心进行评估 如有必要,与内部咨询委员会协商修订方案指导 委员会和NCI计划工作人员。严格审查项目和活动的有效性将使 在实现伙伴关系促进所服务社区卫生公平的目标方面取得进展。
英文摘要
ABSTRACT The Planning & Evaluation Core (P&E Core) of the Partnership for the Advancement of Cancer Research between New Mexico State University (NMSU) and Fred Hutchinson Cancer Center (Fred Hutch) coordinates critical functions necessary for the determination of the impact and effectiveness of Partnership activities in the attainment of its goals and objectives. P&E Core Leads, Dr. Rachel Boren at NMSU and Dr. Julian Simon at Fred Hutch have extensive expertise in program evaluation methodologies. Dr. Boren is Director of the Southwest Outreach Academic Research (SOAR) Evaluation and Policy Center at New Mexico State University and has been an evaluator for over 10 years. She has previously worked as an evaluator for the Institute of Translational Health Sciences (ITHS) based at the University of Washington. Fred Hutch is affiliated with the University of Washington and participates in the ITHS thus giving Dr. Boren a unique familiarity with both institutions. Dr. Simon has served as Research Project and Core Lead as well currently serving as MPI for the Partnership. His nearly 20-year involvement with the Partnership gives him a historical perspective on the culture of the collaboration. The five Specific Aims of the P&E Core are to: 1. Provide assessment tools to evaluate, track and report on progress in all aspects of the Partnership; 2. Release Requests for Applications for new pilot and full Research Projects and conduct rigorous review of proposals; 3. Engage community members and community action boards to evaluate impact of the Partnership on advancing regional cancer health equity; 4. Convene IAC and PSC to review progress of Cores and Research Projects, and facilitate communication between the advisory bodies, NCI and Core and Project Leads, and; 5. Evaluate the implementation and impact of the Guiding Principles (described in detail in Overall). In order to accomplish these Aims, the P&E Core will work with the MPIs (Drs. Graciela Unguez and Julian Simon) as well as Research Project and Core Leads to develop appropriate evaluation instruments to inform on the effectiveness of the Partnership’s activities. Quantitative and qualitative measure of outcomes will be collected and assessed based on the metrics described in the Logic Model (see P&E Core). New Research Projects will be solicited, evaluated, and implemented through the P&E Core. Current Research Projects and Cores will be evaluated and if necessary revised in consultation with the Internal Advisory Committee, the Program Steering Committee and NCI Program Staff. Rigorous review of the effectiveness of projects and activities will enable progress to meeting the Partnership’s goal of advancing health equity in the communities served.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Inhibition of B-Catenin Signaling for Treatment of Hepatocellular Carcinoma
Inhibition of B-Catenin Signaling for Treatment of Hepatocellular Carcinoma
Chemoprotection Against Aminoglycoside-Induced Ototoxicity
Chemoprotection Against Aminoglycoside-Induced Ototoxicity
海外基金